EBMT 2024 | Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti, MD, Humanitas Research Hospital, Milan, Italy, discusses the findings of a single-center retrospective study that compared salvage therapy with checkpoint inhibitors versus brentuximab vedotin in patients receiving allogeneic stem cell transplantation (alloSCT) for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Salvage therapy with checkpoint inhibitors resulted in a lower incidence of relapse, confirming the findings of prior studies in this patient population. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So this is actually a retrospective, another retrospective study that we performed at our single center institution in Milan. And this study was concerned about patients with Hodgkin lymphoma receiving allogeneic transplantation. And we actually compared patients receiving allogeneic transplantation who actually received transplantation. And some of them received brentuximab vedotin with alone or other received also checkpoint inhibitors before allogeneic transplantation...
So this is actually a retrospective, another retrospective study that we performed at our single center institution in Milan. And this study was concerned about patients with Hodgkin lymphoma receiving allogeneic transplantation. And we actually compared patients receiving allogeneic transplantation who actually received transplantation. And some of them received brentuximab vedotin with alone or other received also checkpoint inhibitors before allogeneic transplantation.
The end point of this study was to compare the relapsed incidence in these two cohorts, because what we know is that from the literature is that patients with Hodgkin lymphoma receiving transplantation after a checkpoint inhibitor have a better outcome compared to historical cohorts, but actually historical cohorts usually include patients receiving chemotherapy. It’s a big mixture. We don’t exactly know what is the historical cohort. In this study, we actually compared patients receiving checkpoint inhibitor in one cohort and and patients receiving brentuximab vedotin in the other cohort. And what we observe is that patients receiving allogeneic transplantation after checkpoint inhibitor, we confirm that they have less relapse incidents, relative to patients not treated with checkpoint inhibitor before allogeneic transplantation. So this is actually basically confirm a little bit of the literature about the better outcome for patients receiving checkpoint inhibitors before allogeneic transplantation. But actually it gives other information because it confirms that actually they are achieving a good response before allogeneic transplantation with the checkpoint inhibitors, it’s a much better outcome compared with patients achieving a good response with brentuximab. Basically, both cohorts went to allogeneic transplantation, in order to receive allogeneic transplantation, they had to achieve partial or complete remission, either with brentuximab or with checkpoint inhibitors. But achieving a good response with checkpoint inhibitors gives you a long term effect that is much improved after a transplant compared with patient receiving brentuximab vedotin.
Read more...
